Detalhe da pesquisa
1.
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.
EBioMedicine
; 98: 104886, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37995467
2.
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
J Hematol Oncol
; 15(1): 109, 2022 08 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35978321
3.
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
J Hematol Oncol
; 16(1): 52, 2023 May 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37158935
4.
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.
Cancer Cell
; 40(5): 441-443, 2022 05 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35390296
5.
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.
Cancer Cell
; 39(11): 1442-1444, 2021 11 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34706273
6.
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.
Cancer Cell
; 39(8): 1028-1030, 2021 08 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34242572